Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

No abstract is available for this paper.

• Publication year

  1999

• Venue

  The Lancet

• Publication date

  1999-12-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(99)05246-0
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Etanercept Therapy in Rheumatoid Arthritis

  1999cited by this paper
• A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

  1999cited by this paper
• Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

  1998cited by this paper
• How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey.

  1998cited by this paper
• Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study

  1998cited by this paper
• Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.

  1997cited by this paper
• Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.

  1996cited by this paper
• Lymphoma and Luekemia in Rheumatoid Arthritis: Are They Associated with Azathioprine, Cyclophosphamide, or Methotrexate?

  1996cited by this paper
• Role of cytokines in rheumatoid arthritis.

  1996cited by this paper
• Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study.

  1996cited by this paper
• Monoclonal anti‐TNFα Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease

  1995cited by this paper
• American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

  1995cited by this paper
• The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis.

  1995cited by this paper
• Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group.

  1995cited by this paper
• Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis

  1994cited by this paper
• Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study.

  1994cited by this paper
• Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis

  1994cited by this paper
• Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.

  1993cited by this paper
• Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.

  1993cited by this paper
• The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis.

  1992cited by this paper
• Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts.

  1990cited by this paper
• The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales.

  1982cited by this paper

• Advances in immune cell-based therapeutic agents for the treatment of inflammation-related diseases

  2026cites this paper
• Irisin, Sclerostin, and Inflammatory Axis: Implication in Bone‐Muscle Wasting Diseases

  2026cites this paper
• Cytokine storm

  2026cites this paper
• Rheumatology 2050: How our specialty is changing

  2025cites this paper
• Evaluation of the risk of heart failure with tumour necrosis factor inhibitors: A large‐scale meta‐analysis in immune‐mediated inflammatory diseases

  2025cites this paper
• Targeting lactate metabolism to restore immune homeostasis: a precision therapeutic paradigm for rheumatoid arthritis

  2025cites this paper
• Long-term effectiveness and safety of methotrexate-tacrolimus combination therapy versus methotrexate monotherapy in reducing rheumatoid arthritis flares after TNF inhibitor discontinuation: a retrospective cohort study

  2025cites this paper
• Immunotherapies for postural orthostatic tachycardia syndrome, other common autonomic disorders, and Long COVID: current state and future direction

  2025cites this paper
• Transforming rheumatoid arthritis care: dynamic budget impact models with ACR to DAS28 mapping for anti-TNFs, JAK inhibitors, and interleukins

  2025cites this paper
• The Tailored Biosimilar Approach: Expectations and Requirements

  2025cites this paper
• The total gut mucosal and fecal bacterial load increases in successful treatment of inflammatory bowel disease with infliximab

  2025cites this paper
• Immune biomarkers as key targets in managing tuberculosis: A systematic review

  2025cites this paper
• Infection Risk in Biological Disease-Modifying Anti-rheumatic Drugs

  2025cites this paper
• Evolving strategies in the treatment of rheumatoid arthritis: a historical perspective

  2025cites this paper
• Global recruitment patterns and placebo responses in clinical trials of rheumatoid arthritis.

  2025cites this paper
• STAT3 phosphorylation in the rheumatoid arthritis immunological synapse.

  2025cites this paper
• Risk of tuberculosis disease in patients receiving TNF-α antagonist therapy: A meta-analysis of randomized controlled trials

  2024cites this paper
• Cellular therapies in rheumatic and musculoskeletal diseases

  2024cites this paper
• Inflammatory setting, therapeutic strategies targeting some pro-inflammatory cytokines and pathways in mitigating ischemia/reperfusion-induced hepatic injury: a comprehensive review

  2024cites this paper
• Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development

  2024cites this paper
• Retrospective analysis of rapid drug desensitization with biologic agents: A single center experience

  2024cites this paper
• An interdisciplinary perspective on peripheral drivers of pain in rheumatoid arthritis

  2024cites this paper
• Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease

  2024cites this paper
• Comparisons of infection events associated with tumor necrosis factor inhibitors in patients with inflammatory arthritis: A systematic review and network meta-analysis

  2024cites this paper
• Management of Psoriasis Patients with Serious Infectious Diseases

  2024influential citation
• Local injection of infliximab into calcinosis lesions in patients with juvenile dermatomyositis (JDM): a clinical trial

  2024cites this paper
• Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA

  2024cites this paper
• Monoclonal antibodies: From magic bullet to precision weapon

  2024cites this paper
• Evaluating the Performance of Two Automated Anti-drug Antibodies Assays for Infliximab and Adalimumab Without Acid Dissociation

  2024cites this paper
• Chronic TNF exposure induces glucocorticoid‐like immunosuppression in the alveolar macrophages of aged mice that enhances their susceptibility to pneumonia

  2024cites this paper
• Streamlining biosimilar development based on 20 years’ experience

  2024cites this paper
• Immune response mechanisms in acute and chronic pancreatitis: strategies for therapeutic intervention

  2023cites this paper
• Population Pharmacokinetics of Ozoralizumab in Patients with Rheumatoid Arthritis

  2023cites this paper
• SLE criteria are by necessity still based on clinical (and immunological) criteria items

  2023cites this paper
• Pharmacological Approaches to Modulate the Scarring Process after Glaucoma Surgery

  2023cites this paper
• The Proportion of Patients With Rheumatoid Arthritis Achieving ACR20/50/70; Consistent Patterns of a 60/40/20 as Demonstrated by a Systematic Review and Meta-analysis

  2023cites this paper
• Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study

  2023cites this paper
• Hypoxia with or without Treadmill Exercises Affects Slow-Twitch Muscle Atrophy and Joint Destruction in a Rat Model of Rheumatoid Arthritis

  2023cites this paper
• JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an in-vitro B cell differentiation model and in patients with rheumatoid arthritis

  2023cites this paper
• Severe myocarditis as a cause of the formation of cardiorenal syndrome in a patient with refractory rheumatoid arthritis

  2022cites this paper
• In-depth bibliometric analysis and current scientific mapping research in the context of rheumatoid arthritis pharmacotherapy.

  2022cites this paper
• Persistence of bDMARD therapy in Rheumatoid Arthritis after first-line TNF-inhibitor failure: the RECORD study of the Italian Society for Rheumatology

  2022cites this paper
• Bayesian network meta-analysis methods for combining individual participant data and aggregate data from single arm trials and randomised controlled trials

  2022cites this paper
• Relative Efficacy and Safety of Anti-Inflammatory Biologic Agents for Osteoarthritis: A Conventional and Network Meta-Analysis

  2022cites this paper
• Efficacy and predictor of anti-TNFα agents in patients with intestinal Behçet's disease

  2022cites this paper
• Current Status, Issues and Future Prospects of Personalized Medicine for Each Disease

  2022cites this paper
• Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration

  2022cites this paper
• TNF inhibitors increase the risk of nontuberculous mycobacteria in patients with seropositive rheumatoid arthritis in a mycobacterium tuberculosis endemic area

  2022cites this paper
• A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population

  2022cites this paper
• Evaluation of Access Disparities to Biologic Disease-Modifying Antirheumatic Drugs in Rural and Urban Communities

  2022cites this paper
• Design, synthesis, anti-inflammatory evaluation and molecular docking of novel thiophen-2-ylmethylene-based derivatives as potential TNF-α production inhibitors.

  2022cites this paper
• Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine

  2022cites this paper
• Physician- and Patient-reported Effectiveness Are Similar for Tofacitinib and TNFi in Rheumatoid Arthritis: Data From a Rheumatoid Arthritis Registry

  2022cites this paper
• Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis

  2022cites this paper
• CD81 inhibition with the cytoplasmic RNA vector producing anti-CD81 antibodies suppresses arthritis in a rat CIA model.

  2022cites this paper
• Dilated cardiomyopathy and chronic cardiac inflammation: Pathogenesis, diagnosis and therapy

  2022cites this paper
• Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates

  2022cites this paper
• Schmerz bei rheumatischen Erkrankungen

  2021cites this paper
• Patient-Reported and Radiographic Outcomes of Joint-Preserving Surgery for Rheumatoid Forefoot Deformities: A Retrospective Case Series with Mean Follow-up of 6 Years.

  2021cites this paper
• OARRR_A_291388 31..43

  2021cites this paper
• Osteoporosis associated with rheumatologic disorders

  2021cites this paper
• Treatment Effectiveness of Biologic-DMARDs and their Impact on Disease Control among Rheumatoid Arthritis Patients

  2021cites this paper
• OARRR_A_282627 139..152

  2021cites this paper
• Fine Comparison of the Efficacy and Safety Between GB242 and Infliximab in Patients with Rheumatoid Arthritis: A Phase III Study

  2021influential citation
• Translational research—from basic science to an approved therapeutic—an overview

  2021cites this paper
• Response Similarity Assessment Between Polyarticular Juvenile Idiopathic Arthritis and Adult Rheumatoid Arthritis for Biologics

  2021cites this paper
• Treadmill running prevents atrophy differently in fast- versus slow-twitch muscles in a rat model of rheumatoid arthritis

  2021cites this paper
• Anti-TNF Therapy and the Risk of Malignancies and Infections in Inflammatory Rheumatic Diseases - Our Experience.

  2021cites this paper
• Back to Basics: Prioritizing Communication as a Key Instrument in Managing Rheumatoid Arthritis

  2021cites this paper
• Baseline predictors of different types of treatment success in rheumatoid arthritis

  2021cites this paper
• Differential role of TNFR1 and TNFR2 in the development of imiquimod‐induced mouse psoriasis

  2021cites this paper
• Immune-mediated inflammatory disease therapeutics: past, present and future

  2021cites this paper
• Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study

  2021cites this paper
• The drug discovery process: From ancient times to the present day

  2021cites this paper
• Determination Total Creatine Kinase Activity and Creatine Kinase Isoenzymes Activities in Patients with Ulcerative Colitis and Crohn’s Disease under Infliximab Therapy

  2021influential citation
• Chronic Pain in Patients with Rheumatoid Arthritis

  2021cites this paper
• Budget Impact of Sequential Treatment with Biologics, Biosimilars, and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Thai Patients with Rheumatoid Arthritis

  2021cites this paper
• The 'cytokine storm': molecular mechanisms and therapeutic prospects.

  2021cites this paper
• Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis

  2021cites this paper
• The response to TNF blockers depending on their comparator in rheumatoid arthritis clinical trials: the lessebo effect, a meta-analysis.

  2021cites this paper
• A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study

  2021cites this paper
• Potential application of measuring serum infliximab levels in rheumatoid arthritis management: A retrospective study based on KURAMA cohort data

  2021cites this paper
• Pott’s Puffy Tumor in an Inflammatory Bowel Disease Patient on Anti-TNF Therapy

  2021cites this paper
• Artritis reumatoide: Tratamiento

  2021cites this paper
• Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.

  2021cites this paper
• Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study

  2021cites this paper
• Pain: A Review of Interleukin-6 and Its Roles in the Pain of Rheumatoid Arthritis

  2021cites this paper
• Ibuprofen-based advanced therapeutics: breaking the inflammatory link in cancer, neurodegeneration, and diseases

  2021cites this paper
• "Extensive Proof-of-Concept Studies in TNF-Alpha Antagonists might be Responsible for A Delay of Patient Access in Pediatric Rheumatology"

  2021cites this paper
• Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis

  2021cites this paper
• Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials

  2021cites this paper
• Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician

  2021cites this paper
• Algorithms using genome-wide association studies for prediction of effectiveness of biologics in rheumatoid arthritis

  2020cites this paper
• Real-world Safety and Effectiveness of Infliximab in Pediatric Patients With Acute Kawasaki Disease: A Postmarketing Surveillance in Japan (SAKURA Study).

  2020cites this paper
• Systematic Review and Meta-analysis Cytopenias among patients with rheumatic diseases using methotrexate: a meta-analysis of randomized controlled clinical trials RHEUMATOLOGY

  2020cites this paper
• The Use of Infliximab (Remicade®) for the Treatment of Rheumatic Diseases at a Tertiary Center in Lebanon: A 17-Year Retrospective Chart Review

  2020cites this paper
• Repeated infliximab injection may shift delayed infusion reactions to acute infusion reactions in patients with psoriasis

  2020cites this paper
• Clinical Validation of a Blood-Based Predictive Test for Stratification of Response to Tumor Necrosis Factor Inhibitor Therapies in Rheumatoid Arthritis Patients

  2020cites this paper
• Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry

  2020cites this paper
• Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: A longitudinal cohort study in the Netherlands

  2020influential citation